Curis Announces Dosing Of First Patient In Phase I CUDC-101 Head And Neck Cancer Combination Trial
Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to
develop next generation targeted small molecule drug candidates for
cancer treatment, today announced that the first patient has been
treated in a Phase...